Effect on the carcinogenesis of male rat bladder cancer of antiandrogen and 5_<alpha>-reductase inhibitor
抗雄激素及5_α-还原酶抑制剂对雄性大鼠膀胱癌癌变的影响
基本信息
- 批准号:05671298
- 负责人:
- 金额:$ 1.28万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (C)
- 财政年份:1993
- 资助国家:日本
- 起止时间:1993 至 1994
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
It has been reported that blocking of androgen inhibits bladder carcinogenesis in male rats. However, the mechanism of action of androgen in bladder carcinogenesis is not known. To investigate this problem, we designed the following study using three antiandrogen drugs that have different mechanisms.We administered 0.05% BBN orally to 117 Wistar rats for 10 weeks, and divided them into 7 treatment groups (control, surgical castration, finasteride, LH-RH agonist, flutamide, LH-RH agonist + finasteride and LH-RH agonist + flutamide). Rats were cystectomized in the 21st week and speciments were examined histopathologically. Results demonstrated that surgical castration and LH-RH agonist treatment (three groups) reduced the incidence of carcinoma significantly and that surgical castration had a greater inhibitory effect than the LH-RH agonist. These observations suggest that androgen acts directly on the bladder mucosa. On the other hand, LH-RH agonist + flutamide showed greater inhibition than LH-RH agonist + finasteride, suggesting that testosterone combines directly with androgen receptor without conversion to DHT.We also investigated the presence of androgen receptors in rat and mouse bladder mucosa using monclonal and polyclonal antibodies and western blotting after homogenation. Results confirmed the existence of monoclonal antibody overlapping nuclei in mouse and rat bladder mucosa, as in accessory sex organs, and recognition of a protein corresponding to the molecular weight of the androgen receptor.
已有报道阻断雄激素可抑制雄性大鼠膀胱癌的发生。然而,雄激素在膀胱癌发生中的作用机制尚不清楚。为了研究这一问题,我们设计了三种不同作用机制的抗雄激素药物。给117只Wistar大鼠灌胃0.05%BBN 10周,并将其分为7个处理组(对照组、手术去势组、非那雄胺组、促黄体生成素激动剂组、氟他胺组、促黄体生成素激动剂+非那雄胺组和促黄体生成素激动剂+氟他胺组)。术后第21周行大鼠膀胱切除,取标本进行组织病理学检查。结果表明,手术去势和促黄体生成素释放激素激动剂治疗(三组)均可显著降低肿瘤发生率,且手术去势对肿瘤的抑制作用大于促黄体生成素释放激素激动剂。这些观察表明,雄激素直接作用于膀胱粘膜。另一方面,促黄体生成素受体激动剂+氟他胺的抑制作用强于促黄体生成素受体激动剂+非那雄胺,表明睾酮直接与雄激素受体结合,而不转化为雄激素受体。此外,我们还利用单抗和多克隆抗体以及匀浆后的免疫印迹技术研究了大鼠和小鼠膀胱粘膜中雄激素受体的存在。结果证实,在小鼠和大鼠膀胱粘膜中存在与附性器官相同的重叠核,并识别与雄激素受体分子量相对应的蛋白质。
项目成果
期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Akaza H.,et al: "Role of attachment and viability of BCG to bladder cancer cells" Cancer. 72. 558-563 (1993)
Akaza H. 等人:“BCG 对膀胱癌细胞的附着和活力的作用”癌症。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Imada S,Akaza H: "Effects and mechanism of androgen in rat bladder carcinogenesis" J.Urol. (発表予定).
Imada S、Akaza H:“雄激素在大鼠膀胱癌发生中的作用和机制”J. Urol。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Akaza H.,et al: "A randomized phase II trial of flutarnide us chlormadinone acetate in previously untreated advanced prostatic cancer" Jpn J Clin Oncol. 23. 178-185 (1993)
Akaza H. 等人:“氟他尼和醋酸氯地孕酮治疗先前未经治疗的晚期前列腺癌的随机 II 期试验”Jpn J Clin Oncol。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Akaza H,et al: "Bacillus Colmette-Guerin treatment of existing popillary bladder cancer and CIS of the bladder" Cancer. 75. 552-559 (1995)
Akaza H 等人:“Bacillus Colmette-Guerin 治疗现有的乳头状膀胱癌和膀胱原位癌”癌症。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Imada S,Akaza H: "Effects and mechanism of androgen in rat bladoler carcinegenesis" J.Urol. (発表予定).
Imada S,Akaza H:“雄激素在大鼠膀胱癌发生中的作用和机制”J. Urol。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AKAZA Hideyuki其他文献
AKAZA Hideyuki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AKAZA Hideyuki', 18)}}的其他基金
The risk evaluation and chemoprevention of the prostate cancer
前列腺癌的风险评估和化学预防
- 批准号:
17015006 - 财政年份:2005
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research on Priority Areas
Bio-chemoprevention of recurrenceof superficial bladder cancer-Mechanisms of inhibition by Lactobacillus casei preparation (BLP) on bladder carcinogenesis-
浅表性膀胱癌复发的生物化学预防-干酪乳杆菌制剂(BLP)抑制膀胱癌发生的机制-
- 批准号:
07807148 - 财政年份:1995
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigation of the male predominance of bladder cancer
膀胱癌男性多发的调查
- 批准号:
62570718 - 财政年份:1987
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似国自然基金
RKTG对ERK信号通路的调控和肿瘤生成的影响
- 批准号:30830037
- 批准年份:2008
- 资助金额:190.0 万元
- 项目类别:重点项目
相似海外基金
Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA men
开发功能性人体细胞模型来研究 AA 和 EA 男性前列腺癌的发生和进展
- 批准号:
10566633 - 财政年份:2023
- 资助金额:
$ 1.28万 - 项目类别:
Gender-Affirming Testosterone Therapy on Breast Cancer Risk and Treatment Outcomes
性别肯定睾酮疗法对乳腺癌风险和治疗结果的影响
- 批准号:
10912193 - 财政年份:2023
- 资助金额:
$ 1.28万 - 项目类别:
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer
利用 PMN 免疫反应克服骨转移性前列腺癌的 ADT 耐药性
- 批准号:
10684116 - 财政年份:2022
- 资助金额:
$ 1.28万 - 项目类别:
Androgen signaling and sterol metabolism in metastatic prostate cancer: Functional and therapeutic implication
转移性前列腺癌中的雄激素信号传导和甾醇代谢:功能和治疗意义
- 批准号:
10201013 - 财政年份:2021
- 资助金额:
$ 1.28万 - 项目类别:
Therapeutic targeting steroid sulfatase for advanced prostate cancer
类固醇硫酸酯酶靶向治疗晚期前列腺癌
- 批准号:
10057773 - 财政年份:2020
- 资助金额:
$ 1.28万 - 项目类别:
Therapeutic targeting steroid sulfatase for advanced prostate cancer
类固醇硫酸酯酶靶向治疗晚期前列腺癌
- 批准号:
10426197 - 财政年份:2020
- 资助金额:
$ 1.28万 - 项目类别:
Therapeutic targeting steroid sulfatase for advanced prostate cancer
类固醇硫酸酯酶靶向治疗晚期前列腺癌
- 批准号:
10622544 - 财政年份:2020
- 资助金额:
$ 1.28万 - 项目类别:
Therapeutic targeting steroid sulfatase for advanced prostate cancer
类固醇硫酸酯酶靶向治疗晚期前列腺癌
- 批准号:
10737796 - 财政年份:2020
- 资助金额:
$ 1.28万 - 项目类别:
Men Moving Forward: A Lifestyle Intervention for African American Prostate Cancer Survivors
男人向前迈进:对非裔美国前列腺癌幸存者的生活方式干预
- 批准号:
10524095 - 财政年份:2018
- 资助金额:
$ 1.28万 - 项目类别:
Men Moving Forward: A Lifestyle Intervention for African American Prostate Cancer Survivors
男人向前迈进:对非裔美国前列腺癌幸存者的生活方式干预
- 批准号:
10208814 - 财政年份:2018
- 资助金额:
$ 1.28万 - 项目类别: